Maze Therapeutics initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and no price target The company’s MZE829, and oral APOL1 inhibitor, ...
DeepSeek effect? Microsoft’s data center pullback sparks questions about AI cost
Is the AI arms race slowing down? Microsoft Corp., a leading contender in the artificial intelligence arena, has reportedly ...